In the present study, we confirmed the expression of CD38 on macrophages in HCC and determined 36 the relationship between CD38 + leukocytes and lymphocytes and patient response to immunotherapy. 37
Using immunohistochemistry, we analysed tissue samples obtained from 20 patients from Singapore 38 with HCC prior to immunotherapy. Tumour infiltrating leukocytes expression within tumour were 39 correlated to the responsiveness of patients to immunotherapy. 40
Expression of CD38 was found within the tumour cells and surrounding immune infiltrates including 41 lymphocytes and macrophages. We then ask whether CD38 expression by the distinct cell 42 populations may acquire theranostic relevance. Patients with higher level of CD38 + immune infiltrate 43 subsets had significantly better response to anti-PD-1 immunotherapy, and this is also true for CD38 + 44 lymphocytes within the tumour microenvironment. In particular, a cut-off of 13.0% positive out of 45 total leukocytes and 12.4% positive out of total lymphocytes is found to be of strong predictive value 46 of responsiveness to immunotherapy treatment, thus a strong theranostic impact is seen by using 47 granting accelerated approval of nivolumab treatment for HCC patients previously treated with 77 sorafenib 10, 11 . 78
Current data showed phase I/II trials with response rates about 20%, and thus a number of different 79 biomarkers that have been proposed to differentiate patients who will benefit from PD-1 80
immunotherapy. In addition to PD-L1 expression as a biomarker for response to immunotherapy, [12] [13] [14] 81 tumour mutation burden (TMB) and microsatellite instability (MSI) have also been proposed as 82 predictive markers for immunotherapy, with these markers depicting the number of neoantigens in 83 the tumour that would potentially be recognized by the immune system. 15 IFNγ gene signature is also 84 used to potentially discriminate responsiveness to PD-1 checkpoint blockade. [16] [17] [18] [19] However, in HCC 85 the use of PDL-1 -cut-off 1% on tumour cells has its limitations in predicting response.
10 Thus, there 86 remains to be seen if there is any robust biomarker in HCC. 87
The tumour microenvironment (TME) has also become of interest to the field of immunotherapy. 88
Under normal conditions, tissue homeostasis acts as barrier against tumour formation, with tumours 89 altering the stromal components during their development and metastasis. The tumour 90 microenvironment is hypoxic and immunosuppressive, and a multifunctional molecule called CD38 91 is involved in this mechanism. CD38 structurally resembles CD1a and serves as an ectozyme in the 92 adenosinergic pathway. 20 In hypoxic environments, NAD + is released by the salvage pathway and 93 hydrolysed by CD38 to form adenosine diphosphate ribose. This is further degraded to adenosine 94 monophosphate (AMP) through the CD38-CD203a-CD73 pathway. Following this, CD73 95 dephosphorylates AMP to adenosine. 21, 22 Accumulated extracellular adenosine then binds to various 96 receptors on a range of immune cells, impeding their infiltration and activation. 23, 24 This represents 97 an alternative immunosuppressive mechanism to the PD-1/PD-L1 pathway. Inhibition of the 98 adenosine pathway has been shown to weaken the intensity of immunosuppression in the TME.
99
Furthermore, reversal of hypoxia via oxygen supplementation in a murine model resulted in a 100 significant reduction in solid tumour growth and metastasis. 26 Similarly, co-treatment with PD-1 101 blockade and adenosine receptor inhibitors has been found to improve immune cell responses and 102 result in increased tumour suppression in various mouse models. 
mIF analysis of TMAs 132
Multiplex immunofluorescence/immunohistochemistry (mIF or mIHC) was performed using an Opal 133
Multiplex fIHC kit (PerkinElmer, Inc., Waltham, MA, USA), as previously described by our group 134 and other studies.
31, 36-47 TMA sections (4 µm thick) were labelled with primary antibodies against 135 CD38, CD8 and CD68, followed by appropriate secondary antibodies. All antibodies used are listed 136 in Supplementary Table 1. This was followed by the application of a fluorophore-conjugated 137 tyramide signal amplification buffer (PerkinElmer, Inc.) and the nuclear counterstain DAPI. A Vectra 138 3 pathology imaging system microscope (PerkinElmer, Inc.) was used to obtain images, and these 139 were analysed using inForm software (version 2.4.2; PerkinElmer, Inc.). We initially sought to verify the expression of CD38 by different immune infiltrates in the HCC 153 samples. A high level of co-localisation between CD38 and CD68 expression was visualised under 154 mIF/mIHC (Fig. 1A) , indicating that CD38 is expressed in macrophages. CD38 was also expressed 155 in CD8 + lymphocytes (Fig. 1B) , and in tumour cells (Fig. 1C) . CD38 staining is seen on tumour cells 156 for 2 out of 36 patients in IHC staining. DAPI Nucleus staining was used to identify the cells. 157
Further analysis showed that expression of CD38 + immune infiltrates in HCC were more in non-158 responders when compared to those who responded to anti-PD-1/PD-L1 treatment (Fig. 2) . 159
CD38+ immune infiltrates are associated with partial responsiveness to anti-PD-1 160 immunotherapy treatment in HCC 161
We further assessed whether the presence of CD38 + immune infiltrate subsets in specific locations 162 affects the responsiveness of patients with HCC to nivolumab. In our study, the response criteria 163
were classified as either response present (including complete and partial response) or no response 164 (including both stable and progressive disease). The response criteria are determined according to the As shown in Fig. 4 , the optimal cut-off for CD38 + leukocyte proportion has been defined using 174 receiver operating characteristic analysis. The cut-off used was 4.4% positive out of total immune 175 infiltrates, and this cut-off achieved 75.0% accuracy, 73.3% specificity and 80.0% sensitivity. The 176 area under curve (AUC) is 0.867. Similarly, the optimal cut-off for CD38 + lymphocytes proportion 177 was defined. The cut-off used was 7.5% positive out of total lymphocytes, and this cut-off was 178 achieved 80.0% accuracy, 80.0% specificity and 80.0% sensitivity. 179
Discussion 180
Cancer immunotherapy is mechanistically different to other treatment modalities, such as cytotoxic 181 therapies and small module inhibitors, as it targets the TME rather than the tumour itself. So far, 182 minimal side effects have been identified, and the potential for application to different types of 183 cancer seems particularly promising. However, the overall patient response rate to PD-1/PD-L1 184 inhibitors remains unsatisfactory, limiting its application in clinical practice. This phenomenon may 185 be the result of variability in the immune microenvironment between different cancers. Thus, further 186 investigation of biomarkers is of the utmost importance to fully understand any associations with 187 clinical outcomes, and identify patients most likely to benefit from treatment. 188
Multiple studies have demonstrated correlations between therapeutic response rates and PD-L1 189 expression in tumours, which are likely due to the close relationship between PD-L1 and PD- 1. 190 Increased PD-L1 expression is generally believed to be associated with increased response rate and 191 improved clinical benefit in PD-1 blockade therapy. However, the conclusions drawn from multiple 192 trials have not always been consistent. [55] [56] [57] [58] [59] [60] Thus, investigation of alternative immunosuppression 193 pathways to PD-1/CTLA-4 is necessary. One such immunosuppressive mechanism proposed to be of 194 relevance is the adenosinergic pathway, where extracellular adenosine exerts local 195 immunosuppression through tumour-intrinsic and host-mediated mechanisms. 196
The adenosinergic pathway involves CD38, which is a multifunctional marker that is expressed in 197 various regulatory cells, including myeloid-derived suppressor cells, mesenchymal stem cells and 198 NK cells. 61 In a recent study, CD38 was found to be expressed by a subset of tumours with high 199 levels of basal or treatment-induced infiltration. 62 In the present study, multiplex IHC revealed the 200 expression of CD38 on the surface of both leukocytes and HCC tumour cells (Fig. 1 Notably, the expression of CD38 was observed on macrophages in human HCC tumour samples. 210
Previously, CD38 was found to be in macrophages isolated from mice 63, 64 , cell lines 65 and on human 211 ex vivo experiments 66 , but there is not much direct evidence on CD38 expression on macrophages in 212 humans. This study confirmed that CD38 is expressed on tumour cells as well as multiple types of 213 immune cells, including macrophages. Further analysis on CD38 expression established that 214 responsiveness to immunotherapy is associated with higher levels of CD38 + immune infiltrates 215 within the TME. This is also true for CD38 + lymphocytes levels within the microenvironment but the 216
CD38
+ macrophages subset did not achieve significance (Fig. 3) , suggesting a role of CD38 + 217 lymphocytes in affecting the response of immunotherapy. CD38 is shown to play an important role in 218 lymphocyte activation.
67 Our lab's previous studies have ascertained the role of activated 219 lymphocytes and CD38 in HCC prognosis, 31 and expression of CD38 in lymphocytes has been 220 shown to be a marker in other cancers. 68 Considering the role of CD38 in the adenosine signaling 221 pathway during hypoxia and the involvement of TILs in pro-inflammatory process, it is possible with 222 anti-PD-1 immunotherapy, these CD38 + lymphocytes are suppressed thereby allowing favourable 223 therapeutic responses. 224
In addition to the usage of PD-1-specific antibodies to treat HCC, other trials have also investigated 225 whether combination immunotherapy can be used to overcome tumour resistance. One such trial is a 226 phase Ib randomised clinical study, evaluating the safety and efficacy of administrating the PD-L1-227 specific antibody atezolizumab with bevacizumab, which is a monoclonal antibody that targets 228 VEGF, as a treatment for HCC. This is an on-going trial that is due for completion in 2021. 69 
229
Potential future directions could include assessing the effects of CD38 + leukocyte density on the 230 response to combined immunotherapy. 231
As previously stated, despite an abundance of biomarkers were proposed as a biomarker for 232 immunotherapy therapy in other cancers, it is yet to been seen if there has been any biomarker for 233 HCC. Our paper has successful demonstrated that CD38 + immune subsets or lymphocytes may also 234 be useful as a biomarker to predict anti-PD-1 immunotherapy response. More studies are needed to 235 confirm this phenomenon. Therefore, we propose to validate further by adopting CD38 IHC or 236 mIF/mIHC staining in clinical practice to identify these patients who will gain benefits remarkably 237 by this adjunctive test as the implementation of personalised medicine. 238
Limitations of the present study include a limited sample size which should be a common limitation 239 for anti-PD-1 immunotherapy study in HCC, but the predictive significance between responders and 240 non-responders were substantial. Moreover, a proportion of our patient cohort received PD-1 241 immunotherapy with another agent, making it a heterogenous population. However, this also reflects 242 more closely to real life clinical practice, as most of the patients would receive combined therapy. 243
Further studies may also be needed to investigate the effect of CD157 on response to anti-PD-1 244 immunotherapy, as this is a CD38 paralogue. The two molecules possess dual receptorial and 245
NADase functions, and CD157 is widely expressed across lymphoid tissues, including immune cells 246 such as lymphocytes and macrophages. 
